Neurocrine Biosciences Unveils Study Results on Valbenazine
Recently, Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced important findings from its Phase 3 KINECT-DCP study. This trial evaluated the effectiveness and safety of valbenazine for individuals with dyskinetic cerebral palsy (DCP). The results, unfortunately, have shown that the study did not meet its primary or key secondary endpoints, raising concerns regarding available treatments for this condition.
Understanding Dyskinetic Cerebral Palsy
Dyskinetic Cerebral Palsy is a form of cerebral palsy characterized by involuntary and uncontrolled movements, affecting around 15% of those diagnosed with CP. Individuals with DCP often struggle with both dystonia and choreoathetosis. This means they might experience muscle contractions that are both sustained and random, leading to significant motor difficulties. Knowing that there are currently no approved therapies targeting these motor impairments underscores the urgency for successful treatments.
The Phase 3 KINECT Study Details
The KINECT-DCP trial stands out as the largest double-blind, placebo-controlled clinical trial aimed at understanding the effects of valbenazine. Participants, ranging from young children to adults, were treated for 14 weeks, after which they had the option to partake in an open-label extension phase. The study primarily aimed to measure improvements in chorea associated with DCP. While the adverse events encountered were in line with what has been observed from valbenazine's history, the overall efficacy results were disappointing.
Quote from the Chief Medical Officer
Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine, expressed disappointment regarding the findings. He indicated a deep appreciation for all involved—patients, families, investigators, and site staff—who made the study possible despite the unfavorable outcome. Such gratitude highlights the collaborative spirit essential in clinical research.
Valbenazine's Role and Future Prospects
Valbenazine itself is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It achieved FDA approval in 2017, making it the first drug approved for treating tardive dyskinesia. Its recent approval for managing chorea associated with Huntington's disease further emphasizes its therapeutic potential. Neurocrine is actively developing next-generation VMAT2 inhibitors, with NBI-1065890 moving into Phase 2 trials aimed at treating tardive dyskinesia by 2026.
Neurocrine's Commitment to Patients
Neurocrine Biosciences has made it their mission to improve the lives of individuals grappling with neurological, neuroendocrine, and neuropsychiatric disorders. Their dedication spans over three decades, and the company prides itself on leveraging insights into the complexities of the brain and body. Through ongoing research and development, they are committed to staying at the forefront of biopharmaceutical innovation, ensuring that patients receive the most promising treatments.
A Detailed Commitment from Neurocrine
The commitment to produce impactful treatments reflects Neurocrine's belief that patients with under-addressed needs deserve solutions that truly work. The KINECT-DCP results emphasize the complexity of treating conditions like DCP, but they also showcase the ongoing dedication of the team at Neurocrine. The company remains focused on reporting exhaustive study details at forthcoming scientific meetings to share insights with the broader medical community.
Frequently Asked Questions
What is the phase of the KINECT study announced?
The KINECT study is a Phase 3 clinical trial investigating valbenazine in patients with dyskinetic cerebral palsy.
What were the findings of the KINECT study?
The study did not meet its primary or key secondary endpoints, indicating valbenazine did not show the expected efficacy for treating dyskinetic cerebral palsy.
Who is Neurocrine Biosciences?
Neurocrine Biosciences is a biopharmaceutical company focused on neuroscience, aiming to develop treatments for neurological and psychiatric disorders.
What is valbenazine used for?
Valbenazine is primarily used to treat tardive dyskinesia and has also recently been approved for chorea associated with Huntington's disease.
What future plans does Neurocrine have for valbenazine?
Neurocrine plans to continue developing valbenazine and is introducing next-generation VMAT2 inhibitors aimed at enhancing treatment options for dyskinesias.
